5 results about "Nicotine replacement" patented technology

Tobacco products comprising smokeless tobacco products and active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel are disclosed. Nicotine replacement therapies comprising active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel. The active ingredient may reduce or eliminate sensory irritation arising due to use of the product. Analgesic compositions comprising active ingredients. Methods of reducing taste and sensory irritation by employing an active ingredient.

This application belongs to the field of food or pharmaceutical technology, specifically relating to a lozenge and its preparation method. The lozenge includes a granular composition comprising the following components: an active substance, a cationic resin, cationic salt sustained-release granules, and a filler; wherein the active substance includes at least one of the following: nicotine or a nicotine derivative. This solution incorporates cationic salt sustained-release granules into the lozenge, which not only effectively prevents the rapid dissolution of the cationic salt, allowing it to maintain an effective concentration in the oral cavity for a prolonged period, thus facilitating sufficient contact with the cationic resin to ensure nicotine replacement, but also regulates the release rate of the cationic salt, thereby regulating the nicotine replacement rate.

A synthetic nicotine substitute for use in a variety of delivery systems, particularly in electronic nicotine delivery systems, such as atomizers, electronic cigarettes, combustion, heat-not-burn products, oral or nasal nicotine delivery systems. (S)-6-methylnicotine, also known as (S)-2-methyl-5-(1-methylpyrrolidine-2-yl) pyridine, is a derivative of nicotine, and the 6-site of the pyridine ring of the (S)-6-methylnicotine is substituted by methyl. Preliminary experimental data show that the efficacy of (S)-6-methylnicotine is about 4-5 times (by weight) of nicotine, the (S)-6-methylnicotine can take effect more quickly, and the nicotine desire can be controlled or met more effectively. The carboxylate is also applicable. The enhanced efficacy enables people to alleviate nicotine craving faster and more effectively with a lower dose, and produces a subjective satisfaction to meet the smoking addiction. This enhanced pharmacological efficacy allows for the use of smaller amounts of active ingredients compared to synthetic nicotine formulations, among other potential benefits.

The present disclosure generally relates to a treatment method for helping a subject quit smoking, the method comprising at least one step of administering to the subject an effective dose of an aqueous solution of protein-enriched tobacco leaf extract while the subject continues to smoke freely.Optionally, the second step comprises providing the subject with at least one product capable of controlling nicotine withdrawal symptoms, such as a nicotine agonist or partial agonist, and / or a nicotine substitute, by one or several optional complementary administrations.The present disclosure also relates to a kit comprising a protein-enriched tobacco leaf extract and at least one product capable of controlling nicotine withdrawal symptoms, such as a nicotine agonist or partial agonist, and / or a nicotine substitute.